Hepatocellular carcinoma (HCC), the most common liver cancer, includes aggressive subtypes resistant to treatment. Researchers from Institute of Science Tokyo, Japan, identified a key mechanism behind one such subtype and developed a mouse model replicating its characteristics. Their study found that combining angiogenesis inhibitors with immune checkpoint blockers effectively disrupted the tumor’s defenses, enabling immune cells to attack. These findings offer a promising strategy for improving treatments and outcomes for patients with aggressive HCC.